When people search for a “monthly Suboxone injection,” they’re looking for something real and specific, but the terminology doesn’t quite match the medication. Understanding the distinction matters, because it connects you to the right treatment option and the right conversation with a provider.
What “Monthly Suboxone Injection” Actually Refers To
Suboxone is a brand-name medication containing buprenorphine and naloxone, dissolved under the tongue once daily. It does not come in an injectable form. When people search for a monthly Suboxone injection, they are describing extended-release buprenorphine injections, specifically FDA-approved products called Sublocade and Brixadi. Buprenorphine is the active ingredient in all of these formulations. Suboxone just happens to be the most recognized brand name in opioid use disorder treatment, so it becomes shorthand for the entire category.
Suboxone vs. Extended-Release Buprenorphine Injection
The difference comes down to how the medication enters your body and how often. Suboxone is a film or tablet dissolved under the tongue every single day, combining buprenorphine with naloxone to deter misuse. Extended-release buprenorphine, by contrast, is injected subcutaneously once a month by a healthcare provider in a clinical setting. The core medication is the same: buprenorphine. The delivery system is entirely different, and that difference changes what daily life looks like in recovery.
Sublocade and Brixadi are the two FDA-approved injectable options currently available. Both deliver buprenorphine through a slow-release mechanism that maintains steady medication levels over roughly 28 to 30 days. For a deeper look at how these products compare and what the injection process actually involves, the clinical details of extended-release buprenorphine are worth reviewing before your first appointment.
Why People Use the Term “Monthly Suboxone Shot”
Suboxone became the dominant brand name in buprenorphine treatment the same way Kleenex became synonymous with tissues. Patients, family members, and even community organizations use “Suboxone shot” or “monthly Suboxone injection” to describe any once-monthly buprenorphine treatment, and providers understand exactly what is meant. The terminology is imprecise, but the intent behind the search is clear: people want to know whether they can receive buprenorphine treatment as a monthly injection rather than a daily dose. The answer is yes, and the product that does it is Sublocade or Brixadi, not Suboxone itself.
How the Monthly Injection Works
A 2018 JAMA study by Haight et al., involving 504 participants, found that monthly buprenorphine injections significantly reduced illicit opioid use compared to placebo across a 24-week treatment period. The mechanism behind that result is straightforward: extended-release buprenorphine uses a polymer depot system that releases medication steadily after a single subcutaneous injection. There are no peaks and valleys in blood levels, which means no windows of low medication concentration where cravings intensify and the temptation to use returns.
What this means in practice: one appointment per month replaces 30 daily doses. Steady blood levels also remove the daily decision of whether to take medication, which eliminates an entire category of treatment friction.
What Happens at the Injection Appointment
The appointment itself is brief. A provider conducts a short clinical assessment, confirms that you’re in a stable condition, and administers the injection subcutaneously, most often in the abdomen. Subcutaneous means just beneath the skin, not into muscle. A small, firm lump forms at the injection site as the depot settles; this is expected and gradually dissolves over the month as the medication releases. A short observation period follows before you leave.
Before receiving the first injection, most patients complete an induction period on sublingual buprenorphine, typically around seven days, to establish a stable baseline and confirm tolerance. Skipping this step or rushing the induction timeline increases the risk of precipitated withdrawal. Ask the prescribing provider at your first appointment exactly what the induction schedule looks like for the specific product being prescribed, and follow it precisely.
Who Qualifies for the Monthly Buprenorphine Injection
Clinical eligibility centers on a diagnosis of moderate-to-severe opioid use disorder, initial stabilization on sublingual buprenorphine, no acute hepatic impairment, and no known hypersensitivity to buprenorphine. NIH clinical trial data confirmed efficacy across patients dependent on heroin, fentanyl, and prescription opioids, so the injection is not limited to any single substance history.
Maryland Medicaid covers extended-release buprenorphine injections, which makes this treatment accessible to a significant portion of the state’s treatment-seeking population. If you’re exploring what Sublocade treatment looks like in Maryland and whether your coverage applies, the most efficient step is to request an insurance verification during the intake call rather than waiting until the appointment.
Important Precautions and Contraindications
Patients with severe liver disease should not receive the injection. Patients who have not completed an adequate induction period on sublingual buprenorphine, or who are still physically dependent on full opioid agonists, are not candidates for the first dose. Certain injection-site conditions can also complicate subcutaneous delivery and need to be disclosed in advance.
Both Sublocade and Brixadi carry a black-box warning related to accidental exposure, and both are dispensed exclusively through a certified REMS program. This means the injection must be administered in a clinical setting by a certified provider. It cannot be dispensed at a pharmacy for self-administration at home. That restriction exists to protect both patients and anyone in the household who could be exposed to the medication accidentally.
Benefits That Make the Injection Worth Considering
A 2020 study published in Addiction (Lofwall et al.) found that patients receiving monthly buprenorphine injections had significantly higher treatment retention at 24 weeks compared to patients on daily sublingual dosing. Retention in treatment is the single strongest predictor of long-term recovery outcomes, so that finding carries real weight. More time in treatment means more opportunity for the behavioral, social, and neurological changes that support sustained recovery.
Three concrete advantages follow from the injection format. First, daily medication management disappears entirely. There are no strips to carry, no doses to remember, no routine to maintain outside of one monthly appointment. Second, diversion risk is eliminated. The injection cannot be shared, sold, or misused the way sublingual medication can. Third, patients who find carrying daily medication strips difficult in workplace or family settings gain privacy and simplicity that daily dosing cannot offer.
If you’re ready to find a provider who offers this format, locating a qualified Sublocade clinic in Maryland is the practical next step after confirming eligibility.
What to Expect in the First 30 Days
Some patients notice a meaningful reduction in cravings within the first week as blood levels stabilize. Others take two to three injection cycles before feeling fully settled. Both experiences are normal. The injection does not produce a high. Buprenorphine’s ceiling effect means it occupies opioid receptors without triggering the euphoria associated with full agonists like heroin or oxycodone, even at higher doses.
Keep a brief daily log of cravings, mood, and sleep during the first month. Bring it to the follow-up appointment. That record gives the provider concrete information to work with when evaluating whether the current treatment plan needs any adjustment.
Side Effects to Know Before Starting
According to MedlinePlus prescribing guidance, the most commonly reported side effects from Sublocade and Brixadi include injection-site reactions such as hardness, itching, or redness at the site, along with headache, nausea, constipation, and fatigue. Injection-site reactions are expected and generally resolve as the depot dissolves over the month.
The side effects that require immediate attention are different in character. Symptoms of overdose, including extreme drowsiness, slowed breathing, and pinpoint pupils, can occur if buprenorphine is combined with CNS depressants like benzodiazepines or alcohol. This interaction is the most serious safety consideration associated with buprenorphine treatment. Tell the provider about every medication, supplement, or substance used before the first injection, not after. That disclosure is what allows the provider to identify and manage risk before it becomes a problem.
How to Start the Conversation With a Provider in Maryland
The 2023 SAMHSA National Survey on Drug Use and Health found that fewer than 20% of people with opioid use disorder receive any form of medication-assisted treatment. That gap between need and access is not primarily a medication problem. It’s an access and information problem, and reaching out to a provider is the move that closes it.
Maryland has multiple treatment locations across Baltimore, College Park, Linthicum Heights, Nottingham, and Owings Mills offering buprenorphine-based treatment covered under Medicaid and commercial insurance plans. If you’ve stabilized on daily Suboxone and want a simpler routine, or if you’re starting treatment and want to understand all available options from the beginning, what to expect from a Sublocade injection in Maryland gives you a clear picture of the process before the first appointment.
The next step is direct: call a Maryland treatment provider this week, ask specifically about extended-release buprenorphine, and request insurance verification during that call. Knowing your coverage before the first appointment removes cost as a barrier and lets you focus on the treatment decision itself.
